Skip to content
Back to meeting Original
Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 3 days agoScore70

APEX-BREAST01

Body · original

APEX-Breast01 Rolditamig DXd (TQB2102, a biparatopic ADC) vs TPC chemo in HER2-low MBC has meaningful efficacy
median PFS 16.4 vs 5.5 mo HR=0.29
OS HR=0.44
ORR 68.8% vs 31.0%
#ESMO26

506 views · 7 likes · 4 reposts · 1 reply

Conference abstracts
LBA27matched by Proffered paper 1: Breast cancer, early and advanced stage

APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r/m BC) - Results from a randomized phase 3 study

https://esmocongress.esmo.org
Replies in this thread
  1. Stephanie Graff, MD, FACP, FASCO@DrSGraff

    How to incorporate in complex landscape of ADCs and variability in available treatments internationally remains unclear. #ESMO26

Source: Stephanie Graff, MD, FACP, FASCO · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.